Gencurix: Seoul court extends suspension of NECA notice through 30 days after main ruling

Gencurix corrected its business suspension filing to reflect a Seoul Administrative Court stay of NECA’s notice through 30 days post verdict. The suspension covers its domestic GenesWell BCT breast cancer prognosis testing service, representing KRW 5.88 billion, or 77.91%, of 2025 revenue.